UPDATE – Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

(NASDAQ:UNCY), FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026 Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with […]

UPDATE – Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

UPDATE – Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission GlobeNewswire January 29, 2026 FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026 Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE)

Palo Alto Networks Completes Chronosphere Acquisition, Unifying Observability and Security for the AI Era

Delivers real-time visibility, monitoring, and protection for the massive data volumes that power AI-driven digital operations As enterprises increasingly rely on AI to run digital operations, protect assets, and drive growth, success depends on one critical factor: trusted, high-quality, real-time data. Palo Alto Networks® (NASDAQ: PANW), the global cybersecurity leader, today announced it has completed

Public Company Director Pay Rises 3% as Board Expectations Expand, New NACD/Pearl Meyer Report Finds

NACD today published its annual Director Compensation Report , the industry standard for public company board pay practices, structures , and trends. The National Association of Corporate Directors® (NACD®) has reported that public company director compensation levels continue to grow modestly, according to NACD’s 27th annual Director Compensation Report,?produced in collaboration with leading compensation and

Newport Healthcare Appoints Brent Nelson, MD, to Chief Innovation & Optimization Officer

New role underscores Newport’s commitment to advancing exceptional, innovative behavioral health care Newport Healthcare, a leading provider of evidence-based behavioral health treatment, today announced the promotion of Brent Nelson, MD to Chief Innovation & Optimization Officer, a newly created executive leadership role reporting directly to the Chief Executive Officer. The role reflects Newport’s organization-wide commitment

Hilb Group Continues to Grow Mid-Atlantic Presence, Acquires Pennsylvania-based Property and Casualty Agency

Hilb Group announced today that it has acquired a Pennsylvania-based property and casualty agency. The acquisition took effect on January 1, 2026, expanding the company’s growing product and service offerings throughout the Mid-Atlantic region. About Hilb Group: The Hilb Group is a leading property and casualty and employee benefits insurance brokerage and advisory firm headquartered

Global Silver Shortage Triggers Historic $100 Breakout and Major Resource Rotation

Issued on behalf of Americore Resources Corp. EquityInsider.com News Commentary — Silver’s explosive climb past $100 per ounce for the first time in history[1] marks a massive structural shift where real discovery momentum has replaced speculation as the main value driver. With China’s new export licensing system now locking down 60% to 70% of the

Mike Meehan joins Corcentric as VP Capital Equipment Solutions

CHERRY HILL, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) — Corcentric, a global leader in fleet, procurement, and finance solutions, is thrilled to announce the addition of Mike Meehan to its Capital Equipment Solutions sales team. A recognized name in the transportation industry, Meehan brings over 25 years of expertise to Corcentric's Fleet Solutions division, reinforcing

Longeveron(R) Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

(NASDAQ:LGVN),(NASDAQ:LGVNR), The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs) Patent issuance contributes to Longeveron's growing international

SemiCab to Exhibit at LINK 2026 by RILA

(NASDAQ:RIME), Company to Showcase Its Revolutionary APEX AI SaaS Solution at Premier US Retail Logistics Trade Show Fort Lauderdale, FL, Jan. 29, 2026 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME) – a leading AI technology company, today announced it will attend and exhibit at the upcoming Link 2026: The Retail Supply Chain Conference.

Scroll to Top